Skip to main content
. 2020 Mar 26;267(7):2029–2041. doi: 10.1007/s00415-020-09777-5

Fig. 4.

Fig. 4

Change from baseline in DAS scores of the principal therapeutic target domain for incobotulinumtoxinA versus placebo at week 4 of the MP. ** p ≤ 0.01. ANCOVA of change in DAS score from baseline to week 4 (incobotulinumtoxinA 400 U, n = 44; incobotulinumtoxinA 250 U, n = 23). DAS disability assessment scale, LS least squares, MP main period, SE standard error